[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562755":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":28,"collaborators":7,"id":30,"slug":7,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":33,"acronym":7,"eligibilityCriteria":34,"healthyVolunteers":31,"sex":35,"minAge":7,"maxAge":7,"enrollmentInfo":36,"targetDuration":7,"studyType":39,"phases":7,"briefSummary":40,"conditions":41,"keywords":43,"overallStatus":11,"whyStopped":7,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":55},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",null,[9],{"facility":10,"status":11,"city":12,"state":13,"zip":14,"country":15,"cosmosGeoPoint":16,"geoPoint":21,"contacts":22},"Institute of Hematology & Blood Diseases Hospital","RECRUITING","Tianjin","Tianjin Municipality","300000","China",{"type":17,"coordinates":18},"Point",[19,20],117.17667,39.14222,{"lat":20,"lon":19},[23],{"name":24,"role":25,"phone":26,"phoneExt":7,"email":27},"Zhen Song, MD","CONTACT","+86 02223909051","cir@ihcams.ac.cn",{"type":29,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100562755",false,"NCT06607289","National Longitudinal Cohort of Hematological Diseases (NICHE) - CART","Inclusion Criteria:\n\n* Patients with clinically diagnosed hematologic malignancies\n* Patients treated with CAR-T cell therapy\n* Signed the informed consent form","ALL",{"count":37,"type":38},1000,"ESTIMATED","OBSERVATIONAL","This is a multicenter, ambispective, longitudinal, observational cohort study investigating CAR-T cell therapy in Chinese patients with hematological malignancies. A consortium of Phase IV clinical trials and real-world studies of Chimeric antigen receptors (CAR) T cell therapy will be established in China. Patient-level data from these studies will be collected to create a large real-world cohort. In addition, patients receiving CAR-T cell therapy for hematological malignancies identified from an existing hematology longitudinal cohort study, the National Longitudinal Cohort of Hematological Diseases (NICHE), will also be included in the study.",[42],"Hematological Malignancies",[44,45],"Chimeric antigen receptors (CAR) T cell","hematological malignancies","2025-06-15",{"date":48,"type":49},"2025-06-17","ACTUAL",{"date":51,"type":49},"2021-06-01",{"date":53,"type":38},"2032-12-31",{"name":5,"class":6},1]